This study used real-world data to compare SGLT-2 inhibitors versus other medications for patients with type 2 diabetes (T2D). It found that SGLT-2 inhibitors led to lower kidney disease and better overall outcomes.

This study investigated the long-term effectiveness and safety of certolizumab pegol (Cimzia) in patients with rheumatoid arthritis (RA) from a real-world practice. They found that this medication was safe and patients had a sustained response. 

This review looked at how SGTL2 inhibitors with or without metformin (Glucophage) affect heart and kidney health for patients with type 2 diabetes (T2D). It found that these medications improve cardiovascular and kidney outcomes, whether or not patients are also taking metformin.

This study compared the traditional diabetic diet (TDD) with a low-carbohydrate diet (LCD) for patients with poorly controlled type 2 diabetes (T2D). They found that the LCD resulted in better blood glucose (sugar) control and reduced need for diabetic medications compared to the TDD.

This study looked at the treatment of severe diabetic macular edema (DME). It compared eyes treated with surgery to eyes treated with injections.  It showed that surgical treatment leads to a better resolution of DME compared to injections.

This study investigated if biological disease-modifying anti-rheumatic drugs (bDMARDs) affect diabetes risk in patients with rheumatoid arthritis (RA).

They found that bDMARD use was associated with lower rates of diabetes in these patients. 

This study examined the risk of major heart complications in patients taking a type of diabetic medication called DPP4-inhibitors. They found that patients taking DPP4-inhibitors were less likely to develop major heart disease than patients taking sulfonylureas. 

This trial is looking to recruit patients with diabetic macular edema (DME) to trial a new gene therapy, ADVM-022. This trial is aiming to measure the time it takes for DME to worsen. This trial is being carried out in Puerto Rico and the United States.

This controlled trial looked at adding exenatide (Byetta) to intensive insulin treatment for patients with type 2 diabetes (T2D) who still had high blood sugar. It found that the exenatide improved blood sugar control and reduced body weight in these patients.

This study investigated if weight changes increase the risk of cardiovascular events (CVEs) in patients with rheumatoid arthritis (RA). They found that a 10% increase or decrease in weight increased the risk of CVEs in these patients.